Sacituzumab is a humanized IgG1 monoclonal antibody that specifically targets Trophoblast cell surface antigen 2 (TROP2). This antibody binds to the linear epitopes of the TROP2 protein. Although Sacituzumab alone does not exhibit antitumor effects or inhibit the function of TROP2 during tumor metastasis, it serves as a foundational component for the development of antibody-drug conjugates (ADCs). A notable application of Sacituzumab is its conjugation with the cytotoxic drug, govitecan, to form Sacituzumab govitecan. This conjugate has demonstrated utility in the treatment of triple-negative breast cancer, highlighting its significant potential in therapeutic applications targeting this challenging oncological condition.
Sacituzumab is a humanized IgG1 monoclonal antibody that specifically targets Trophoblast cell surface antigen 2 (TROP2). This antibody binds to the linear epitopes of the TROP2 protein. Although Sacituzumab alone does not exhibit antitumor effects or inhibit the function of TROP2 during tumor metastasis, it serves as a foundational component for the development of antibody-drug conjugates (ADCs). A notable application of Sacituzumab is its conjugation with the cytotoxic drug, govitecan, to form Sacituzumab govitecan. This conjugate has demonstrated utility in the treatment of triple-negative breast cancer, highlighting its significant potential in therapeutic applications targeting this challenging oncological condition.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
